Bivalirudin and DES: a PCI strategy that pays.
Applegate
Robert J
RJ
Section of Cardiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
D000925:Anticoagulants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000628:therapy; D003365:Costs and Cost Analysis; D016503:Drug Delivery Systems; D006493:Heparin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D006629:Hirudins / Q000009:adverse effects / Q000191:economics; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007902:Length of Stay / Q000191:economics; D009203:Myocardial Infarction / Q000188:drug therapy / Q000191:economics* / Q000517:prevention & control*; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D010446:Peptide Fragments / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D020123:Sirolimus / Q000008:administration & dosage / Q000627:therapeutic use; D015607:Stents / Q000191:economics
D000925:Anticoagulants; D006629:Hirudins; D007166:Immunosuppressive Agents; D010446:Peptide Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D006493:Heparin; D017239:Paclitaxel; C074619:bivalirudin; D020123:Sirolimus